Macquarie sees mid-teens earnings risk for Max Health stock

Published on 10/12/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Macquarie sees mid-teens EBITDA risk from a proposed 30 percent drug cap. The October 12 hearing tests Max Health stock.

Key points in brief

Macquarie analyst Kunal Dhamesha warned that a proposed 30 percent cancer-drug markup cap could cut Max Healthcare's EBITDA by the mid-teens.
Max Healthcare reported Q1 FY27 revenue of INR 28.35 billion, up 15.20 percent year over year, according to DSIJ.
The company had a market capitalization of INR 858.6 billion as of October 12, 2026, while the Supreme Court hearing was scheduled for October 12, 2026.

Max Health, INE027H01010, Illustration mit AI erstellt.

Macquarie analyst Kunal Dhamesha said a proposed 30 percent markup cap on certain cancer drugs could cut Max Healthcare Institute's earnings before interest, taxes, depreciation and amortization by the mid-teens if hospitals absorb the impact. TradingView reported the assessment on October 9, 2026, ahead of the Supreme Court hearing scheduled for October 12, 2026.

Three events shape the story

On August 17, 2026, Anand Rathi Research retained its Buy recommendation and INR 1,220 target for Max Healthcare, while raising its fiscal-year estimates. DSIJ said the broker expected revenue and EBITDA to compound at 18 percent each from fiscal 2026 to fiscal 2028.

On October 6, 2026, a Q1 FY27 earnings-call summary showed network gross revenue of INR 29.82 billion, up 16 percent year over year, and operating EBITDA of INR 7.04 billion, up 15 percent. The same summary put the operating margin at 24.80 percent and brownfield occupancy at 80 percent. Quartrly also reported management's plan to enter medical education with INR 3.00 billion of capital spending per college.

On October 9, 2026, the regulatory issue became the immediate counterweight to that expansion story. A 30 percent markup ceiling would be materially below the average oncology-drug markup of 170 percent cited in the same TradingView report, leaving pharmacy economics and hospital margins as the central variables.

What does the cap mean for margins?

The near-term sensitivity is clear in the gap between revenue and profit growth. DSIJ said Max Healthcare's Q1 FY27 consolidated revenue rose 15.20 percent year over year to INR 28.35 billion, while the analyst forecast revenue and EBITDA growth of 18 percent annually through fiscal 2028. DSIJ described oncology pressure as a factor in the quarter, making the markup proposal relevant to the valuation case rather than a separate policy headline.

Dates investors are watching

The Supreme Court hearing was scheduled for October 12, 2026, according to TradingView. The next quarterly results were listed for November 6, 2026, by TickerLandia.

Market value and operating scale

Max Healthcare had a market capitalization of INR 858.6 billion as of October 12, 2026. The company operates 21 healthcare facilities with more than 6,100 beds, alongside homecare and pathology businesses, according to its investor-relations page. Its scale supports expansion, but the proposed drug-price intervention puts a direct regulatory question beside the growth figures.